SYNRIBO is a Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Cephalon, Inc.. The primary component is Omacetaxine Mepesuccinate.
Product ID | 63459-177_32221c80-ccf1-4539-b41b-b4cbede7d5e0 |
NDC | 63459-177 |
Product Type | Human Prescription Drug |
Proprietary Name | SYNRIBO |
Generic Name | Omacetaxine Mepesuccinate |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2012-11-19 |
Marketing Category | NDA / NDA |
Application Number | NDA203585 |
Labeler Name | Cephalon, Inc. |
Substance Name | OMACETAXINE MEPESUCCINATE |
Active Ingredient Strength | 4 mg/mL |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2012-11-19 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA203585 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2012-11-19 |
Ingredient | Strength |
---|---|
OMACETAXINE MEPESUCCINATE | 3.5 mg/mL |
SPL SET ID: | 83a504ef-cf92-467d-9ecf-d251194a3484 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SYNRIBO 85514017 4277076 Live/Registered |
TEVA PHARMACEUTICALS INTERNATIONAL GMBH 2012-01-11 |